

**Enovix Corporation (Nasdaq: ENVX)**

**Financial Supplement**

GAAP Income Statement (in thousands, except Share and per Share amounts)	Unaudited										See Note 1	
	Q1-23	Q2-23	Q3-23	Q4-23	Q1-24	Q2-24	Q3-24	Q4-24	Q1-25	Q2-25	FY23	FY24
Revenue	\$ 21	\$ 42	\$ 200	\$ 7,381	\$ 5,272	\$ 3,768	\$ 4,317	\$ 9,717	\$ 5,098	\$ 7,468	\$ 7,644	\$ 23,074
Cost of revenue	12,248	14,235	16,809	19,769	7,072	4,423	4,959	8,665	4,837	5,526	63,061	25,119
Gross profit	(12,227)	(14,193)	(16,609)	(12,388)	(1,800)	(655)	(642)	1,052	261	1,942	(55,417)	(2,045)
Operating expenses:												
Research and development	23,749	16,553	13,508	34,582	48,788	29,065	24,220	22,433	25,929	28,148	88,392	124,506
Selling, general and administrative	27,274	16,688	17,245	17,807	19,548	20,884	20,744	13,135	16,892	17,527	79,014	74,311
Impairment of equipment	-	4,411	-	-	-	-	-	-	-	-	4,411	-
Restructuring cost	-	-	3,021	-	-	38,146	3,661	-	-	-	3,021	41,807
Total operating expenses	51,023	37,652	33,774	52,389	68,336	88,095	48,625	35,568	42,821	45,675	174,838	240,624
Loss from operations	(63,250)	(51,845)	(50,383)	(64,777)	(70,136)	(88,750)	(49,267)	(34,516)	(42,560)	(43,733)	(230,255)	(242,669)
Other income (expense):												
Change in fair value of common stock	(12,840)	(14,340)	31,320	2,040	21,120	(33,660)	29,899	(5,115)	15,796	(5,885)	6,180	12,244
Gain on bargain purchase of assets	-	-	-	-	-	-	-	-	-	4,761	-	-
Interest income	2,466	3,150	4,326	4,128	3,560	3,326	2,859	2,587	2,434	2,427	14,070	12,332
Interest expense	-	(1,270)	(1,557)	(1,629)	(1,659)	(1,691)	(1,718)	(1,719)	(1,716)	(1,705)	(4,456)	(6,787)
Other income (loss), net	21	(1)	109	(433)	466	242	(2,217)	2,463	2,353	(992)	(304)	954
Total other income (loss), net	(10,353)	(12,461)	34,198	4,106	23,487	(31,783)	28,823	(1,784)	18,867	(1,394)	15,490	18,743
Loss before income tax expense (benefit)	(73,603)	(64,306)	(16,185)	(60,671)	(46,649)	(120,533)	(20,444)	(36,300)	(23,693)	(45,127)	(214,765)	(223,926)
Income tax expense (benefit)	-	-	-	(633)	(152)	(4,586)	2,194	1,152	(162)	(861)	(633)	(1,392)
Net loss	(73,603)	(64,306)	(16,185)	(60,038)	(46,497)	(115,947)	(22,638)	(37,452)	(23,531)	(44,266)	(214,132)	(222,534)
Net gain (loss) attributable to non-controlling interest	-	-	-	(61)	(129)	(75)	(102)	13	(21)	262	(61)	(293)
Net loss attributable to Enovix	\$ (73,603)	\$ (64,306)	\$ (16,185)	\$ (59,977)	\$ (46,368)	\$ (115,872)	\$ (22,536)	\$ (37,465)	\$ (23,510)	\$ (44,528)	\$ (214,071)	\$ (222,241)
Net loss per share attributable to Enovix shareholders, basic	\$ (0.44)	\$ (0.38)	\$ (0.10)	\$ (0.34)	\$ (0.26)	\$ (0.63)	\$ (0.12)	\$ (0.19)	\$ (0.12)	\$ (0.22)	\$ (1.27)	\$ (1.19)
Weighted average number of common shares outstanding, basic (million) <sup>3</sup>	165.4	167.0	169.9	176.1	178.7	183.3	187.8	196.6	203.4	204.8	169.1	186.1
Net loss per share attributable to Enovix shareholders, diluted	\$ (0.44)	\$ (0.38)	\$ (0.28)	\$ (0.34)	\$ (0.26)	\$ (0.63)	\$ (0.28)	\$ (0.19)	\$ (0.12)	\$ (0.22)	\$ (1.30)	\$ (1.19)
Weighted average number of common shares outstanding, diluted (million) <sup>3</sup>	165.4	167.0	171.4	176.1	178.7	183.3	188.0	196.6	203.4	204.8	169.6	186.1

Non-GAAP Income Statement (See Note 2) (in thousands, except Share and per Share amounts)	Unaudited										Unaudited	
	Q1-23	Q2-23	Q3-23	Q4-23	Q1-24	Q2-24	Q3-24	Q4-24	Q1-25	Q2-25	FY23	FY24
Revenue	\$ 21	\$ 42	\$ 200	\$ 7,381	\$ 5,272	\$ 3,768	\$ 4,317	\$ 9,717	\$ 5,098	\$ 7,468	\$ 7,644	\$ 23,074
Non-GAAP Cost of revenue	11,297	12,581	14,413	17,104	5,165	4,328	4,858	8,541	4,716	5,170	55,395	22,892
Non-GAAP Gross profit	(11,276)	(12,539)	(14,213)	(9,723)	107	(560)	(541)	1,176	382	2,298	(47,751)	182
Non-GAAP Operating expenses:												
Non-GAAP Research and development	12,082	11,097	8,559	28,968	41,818	21,347	17,889	16,935	19,158	20,792	60,706	97,989
Non-GAAP Selling, general and administrative	10,596	8,674	10,034	10,826	12,444	9,053	8,462	9,368	9,176	8,018	40,130	39,327
Total Non-GAAP operating expenses	22,678	19,771	18,593	39,794	54,262	30,400	26,351	26,303	28,334	28,810	100,836	137,316
Loss from operations	(33,954)	(32,310)	(32,806)	(49,517)	(54,155)	(30,960)	(26,892)	(25,127)	(27,952)	(26,512)	(148,587)	(137,134)
Other income (expense):												
Interest income	2,466	3,150	4,326	4,128	3,560	3,326	2,859	2,587	2,434	2,427	14,070	12,332
Interest expense	-	(1,270)	(1,557)	(1,629)	(1,659)	(1,691)	(1,718)	(1,719)	(1,716)	(1,705)	(4,456)	(6,787)
Other income (loss), net	21	(1)	109	(433)	466	242	(2,217)	2,463	(78)	(992)	(304)	954
Total other income (loss), net	2,487	1,879	2,878	2,066	2,367	1,877	(1,076)	3,331	640	(270)	9,310	6,499
Loss before income tax expense (benefit)	(31,467)	(30,431)	(29,928)	(47,451)	(51,788)	(29,083)	(27,968)	(21,796)	(27,312)	(26,782)	(139,277)	(130,635)
Income tax expense (benefit)	-	-	-	(633)	(152)	(4,586)	2,194	1,152	(162)	(861)	(633)	(1,392)
Net loss	(31,467)	(30,431)	(29,928)	(46,818)	(51,636)	(24,497)	(30,162)	(22,948)	(27,150)	(25,921)	(138,644)	(129,243)
Net gain (loss) attributable to non-controlling interest	-	-	-	(61)	(129)	(75)	(102)	13	(21)	262	(61)	(293)
Net loss attributable to Enovix	\$ (31,467)	\$ (30,431)	\$ (29,928)	\$ (46,757)	\$ (51,507)	\$ (24,422)	\$ (30,060)	\$ (22,961)	\$ (27,129)	\$ (26,183)	\$ (138,583)	\$ (128,950)
Non-GAAP Net loss per share attributable to Enovix shareholders, basic <sup>3</sup>	\$ (0.19)	\$ (0.18)	\$ (0.18)	\$ (0.27)	\$ (0.29)	\$ (0.13)	\$ (0.16)	\$ (0.12)	\$ (0.13)	\$ (0.13)	\$ (0.82)	\$ (0.69)
Weighted average number of common shares outstanding, basic (million)	165.4	167.0	169.9	176.1	178.7	183.3	187.8	196.6	203.4	204.8	169.1	186.1
Non-GAAP Net loss per share attributable to Enovix shareholders, diluted <sup>3</sup>	\$ (0.19)	\$ (0.18)	\$ (0.17)	\$ (0.27)	\$ (0.29)	\$ (0.13)	\$ (0.16)	\$ (0.12)	\$ (0.13)	\$ (0.13)	\$ (0.82)	\$ (0.69)
Weighted average number of common shares outstanding, diluted (million)	165.4	167.0	171.4	176.1	178.7	183.3	188.0	196.6	203.4	204.8	169.6	186.1

**Note 1:** Annual figures derived from audited consolidated financial statements which are available in our Form 10-K filings at SEC.GOV.

**Note 2:** The non-GAAP measures presented should not be considered a substitute for the financial results and measures determined or calculated in accordance with GAAP.

See Appendix I for more information and a reconciliation of GAAP to non-GAAP Financial Measures

**Note 3:** As required by ASC 260, Earnings Per Share, the share and per share amounts in the condensed consolidated financial statements for the periods presented above have been retroactively adjusted to reflect the warrant dividends issued in July 2025.

## EBITDA and Adjusted EBITDA

**EBITDA and Adjusted EBITDA Reconciliation** - Below we provide a reconciliation of GAAP net loss attributable to Enovix to EBITDA and adjusted EBITDA for the periods presented (preliminary and unaudited) (in thousands). We define EBITDA as net loss attributable to Enovix adjusted for interest expense, interest income, income tax expense(benefit), and depreciation and amortization expense. Adjusted EBITDA is defined as EBITDA further adjusted for stock-based compensation expense, change in fair value of common stock warrants, inventory step-up, import duty forgiveness, acquisition costs, restructuring costs, legal expenses related to shareholder lawsuit net of insurance proceeds, impairment of equipment and other special items not indicative of our core operating performance, as determined by management. These non-GAAP measures may differ from similarly titled measures used by other

Reconciliation to EBITDA and Adjusted EBITDA (in thousands)	Unaudited										Unaudited	
	Q1-23	Q2-23	Q3-23	Q4-23	Q1-24	Q2-24	Q3-24	Q4-24	Q1-25	Q2-25	FY23	FY24
Net loss attributable to Enovix	(73,603)	(64,306)	(16,185)	(59,977)	(46,368)	(115,872)	(22,536)	(37,465)	(23,510)	(44,528)	(214,071)	(222,241)
Interest expense (income), net	(2,466)	(1,880)	(2,769)	(2,499)	(1,901)	(1,635)	(1,141)	(868)	(718)	(722)	(9,614)	(5,545)
Income tax expense (benefit)	-	-	-	(633)	(152)	(4,586)	2,194	1,152	(162)	(861)	(633)	(1,392)
Depreciation and amortization	3,598	3,502	2,900	24,009	24,974	5,943	6,500	7,544	8,448	8,829	34,009	44,961
<b>EBITDA</b>	<b>(72,471)</b>	<b>(62,684)</b>	<b>(16,054)</b>	<b>(39,100)</b>	<b>(23,447)</b>	<b>(116,150)</b>	<b>(14,983)</b>	<b>(29,637)</b>	<b>(15,942)</b>	<b>(37,282)</b>	<b>(190,309)</b>	<b>(184,217)</b>
Stock-based compensation expense	29,157	15,042	13,274	11,620	12,760	17,932	16,722	10,207	12,014	14,122	69,093	57,621
Change in fair value of common stock warrants	12,840	14,340	(31,320)	(2,040)	(21,120)	33,660	(29,899)	5,115	(15,796)	5,885	(6,180)	(12,244)
Inventory step-up	-	-	-	2,206	1,907	-	-	-	-	-	2,206	1,907
Impairment of equipment	-	4,411	-	-	-	-	-	-	-	-	4,411	-
Restructuring cost	-	-	3,021	-	-	38,146	3,661	-	-	-	3,021	41,807
Legal expenses related to shareholder lawsuit, net	139	82	167	463	142	523	801	(2,007)	1,404	1,247	851	(541)
Acquisition cost	-	-	1,115	158	-	-	-	-	-	664	1,273	-
Gain on bargain purchase of assets	-	-	-	-	-	-	-	-	-	(4,761)	-	-
Import duty forgiveness	-	-	-	-	-	-	-	-	(2,431)	-	-	-
<b>Adjusted EBITDA</b>	<b>(30,335)</b>	<b>(28,809)</b>	<b>(29,797)</b>	<b>(26,693)</b>	<b>(29,758)</b>	<b>(25,889)</b>	<b>(23,698)</b>	<b>(16,322)</b>	<b>(20,751)</b>	<b>(20,125)</b>	<b>(115,634)</b>	<b>(95,667)</b>

**Reconciliation of Operating Loss to Non-GAAP Operating Loss and Adjusted EBITDA** Additionally, below is a reconciliation of GAAP operating loss to non-GAAP operating loss and adjusted EBITDA for the periods presented (preliminary and unaudited) (in thousands). These non-GAAP measures may differ from similarly titled measures used by other companies.

Reconciliation to GAAP Operating Loss and to Adjusted EBITDA (in thousands)	Unaudited										Unaudited	
	Q1-23	Q2-23	Q3-23	Q4-23	Q1-24	Q2-24	Q3-24	Q4-24	Q1-25	Q2-25	FY23	FY24
GAAP Operating Loss	(63,250)	(51,845)	(50,383)	(64,777)	(70,136)	(88,750)	(49,267)	(34,516)	(42,560)	(43,733)	(230,255)	(242,669)
Stock-based compensation expense	29,157	15,042	13,274	11,620	12,760	17,932	16,722	10,207	12,014	14,122	69,093	57,621
Amortization of intangible assets	-	-	-	813	1,172	1,189	1,191	1,189	1,190	1,188	813	4,741
Inventory step-up	-	-	-	2,206	1,907	-	-	-	-	-	2,206	1,907
Impairment of equipment	-	4,411	-	-	-	-	-	-	-	-	4,411	-
Restructuring cost	-	-	3,021	-	-	38,146	3,661	-	-	-	3,021	41,807
Legal expenses related to shareholder lawsuit, net	139	82	167	463	142	523	801	(2,007)	1,404	1,247	851	(541)
Acquisition cost	-	-	1,115	158	-	-	-	-	-	664	1,273	-
<b>Non-GAAP Operating Loss</b>	<b>(33,954)</b>	<b>(32,310)</b>	<b>(32,806)</b>	<b>(49,517)</b>	<b>(54,155)</b>	<b>(30,960)</b>	<b>(26,892)</b>	<b>(25,127)</b>	<b>(27,952)</b>	<b>(26,512)</b>	<b>(148,587)</b>	<b>(137,134)</b>
Depreciation and amortization (excluding amortization of intangible assets)	3,598	3,502	2,900	23,196	23,802	4,754	5,309	6,355	7,258	7,641	33,196	40,220
Other income (loss), net (excluding import duty forgiveness)	21	(1)	109	(433)	466	242	(2,217)	2,463	(78)	(992)	(304)	954
Net loss attributable to non-controlling interest	-	-	-	61	129	75	102	(13)	21	(262)	61	293
<b>Adjusted EBITDA</b>	<b>(30,335)</b>	<b>(28,809)</b>	<b>(29,797)</b>	<b>(26,693)</b>	<b>(29,758)</b>	<b>(25,889)</b>	<b>(23,698)</b>	<b>(16,322)</b>	<b>(20,751)</b>	<b>(20,125)</b>	<b>(115,634)</b>	<b>(95,667)</b>

Cash, Cash Equivalents and Marketable Securities and Free Cash Flow

Cash, Cash Equivalents and Marketable Securities (in thousands)	Unaudited										Unaudited	
	Q1-23	Q2-23	Q3-23	Q4-23	Q1-24	Q2-24	Q3-24	Q4-24	Q1-25	Q2-25	FY23	FY24
Cash, Cash Equivalents and Marketable Securities	\$ 293,751	\$ 409,244	\$ 371,399	\$ 307,815	\$ 262,393	\$ 249,929	\$ 200,912	\$ 272,869	\$ 248,155	\$ 203,412	\$ 306,815	\$ 272,869

**Free Cash Flow Reconciliation**

We define Free Cash Flow as net cash used in operating activities less capital expenditures, net of proceeds from disposals of property and equipment, each as reported in our consolidated statements of cash flows. Free Cash Flow is a non-GAAP financial measure and should not be considered an alternative to cash flows from operating activities as determined in accordance with GAAP.

We believe Free Cash Flow is a useful measure for investors because it provides insight into the cash generated or used by our operations after funding capital expenditures, and it helps assess our ability to pursue strategic growth initiatives. We use Free Cash Flow internally to evaluate performance, support decision-making, and measure our progress toward profitability and cash flow breakeven.

This non-GAAP measure may differ from similarly titled measures used by other companies.

Below is a reconciliation of net cash used in operating activities to the Free Cash Flow financial measure for the periods presented (preliminary and unaudited) (in thousands):

Free Cash Flow (See Note 2) (in thousands)	Unaudited										Unaudited	
	Q1-23	Q2-23	Q3-23	Q4-23	Q1-24	Q2-24	Q3-24	Q4-24	Q1-25	Q2-25	FY23	FY24
Net cash used in operating activities	\$ (25,611)	\$ (23,552)	\$ (28,245)	\$ (27,228)	\$ (35,044)	\$ (26,949)	\$ (30,682)	\$ (15,958)	\$ (16,907)	\$ (25,859)	\$ (104,636)	\$ (108,633)
Capital expenditures	(3,032)	(12,692)	(17,255)	(28,816)	(15,088)	(25,209)	(19,533)	(16,358)	(6,272)	(7,971)	(61,795)	(76,188)
Acquisition of SETK Assets	-	-	-	-	-	-	-	-	-	(10,000)	-	-
Free Cash Flow	\$ (28,643)	\$ (36,244)	\$ (45,500)	\$ (56,044)	\$ (50,132)	\$ (52,158)	\$ (50,215)	\$ (32,316)	\$ (23,179)	\$ (43,830)	\$ (166,431)	\$ (184,821)

**Non-GAAP Financial Measures**

This financial supplement includes the use of non-GAAP financial measures, which are intended to provide supplemental information regarding our performance. These non-GAAP measures include non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP gross margin, non-GAAP research and development expense, non-GAAP selling, general and administrative expense, non-GAAP operating expenses, non-GAAP operating income (loss), EBITDA, adjusted EBITDA, non-GAAP net income (loss) attributable to Enovix shareholders, non-GAAP earnings (loss) per share, free cash flow, and other non-GAAP measures.

We use these non-GAAP measures to supplement our financial reporting and to evaluate ongoing operations and results, facilitate internal planning and forecasting, and assess performance against prior periods, industry peers, and the broader market. These non-GAAP measures are not prepared in accordance with generally accepted accounting principles (GAAP) and should not be considered as an alternative to GAAP results. Industry peers and other companies may calculate similar non-GAAP measures differently. Non-GAAP financial measures have limitations, including but not limited to, that they exclude certain expenses that are required under GAAP, which adjustments reflect the exercise of judgment by management. We believe that these non-GAAP measures, when considered together with the GAAP results, provide investors with an additional understanding of our operating performance. Reconciliations of each non-GAAP financial measure to the most directly comparable GAAP financial measure can be found in the tables at the end of this shareholder letter.

Other Non-GAAP Financial Measures Reconciliation (in thousands, except Share and per Share amounts)	Unaudited										Unaudited	
	Q1-23	Q2-23	Q3-23	Q4-23	Q1-24	Q2-24	Q3-24	Q4-24	Q1-25	Q2-25	FY23	FY24
GAAP cost of revenue	\$ 12,248	\$ 14,235	\$ 16,809	\$ 19,769	\$ 7,072	\$ 4,423	\$ 4,959	\$ 8,665	\$ 4,837	\$ 5,526	\$ 63,061	\$ 25,119
Stock-based compensation expense	(951)	(1,654)	(2,396)	(459)	-	(95)	(101)	(124)	(121)	(356)	(5,460)	(320)
Inventory step-up	-	-	-	(2,206)	(1,907)	-	-	-	-	-	(2,206)	(1,907)
Non-GAAP cost of revenue	\$ 11,297	\$ 12,581	\$ 14,413	\$ 17,104	\$ 5,165	\$ 4,328	\$ 4,858	\$ 8,541	\$ 4,716	\$ 5,170	\$ 55,395	\$ 22,892
GAAP gross profit	\$ (12,227)	\$ (14,193)	\$ (16,609)	\$ (12,388)	\$ (1,800)	\$ (655)	\$ (642)	\$ 1,052	\$ 261	\$ 1,942	\$ (55,417)	\$ (2,045)
Stock-based compensation expense	951	1,654	2,396	459	-	95	101	124	121	356	5,460	320
Inventory step-up	-	-	-	2,206	1,907	-	-	-	-	-	2,206	1,907
Non-GAAP gross profit	\$ (11,276)	\$ (12,539)	\$ (14,213)	\$ (9,723)	\$ 107	\$ (560)	\$ (541)	\$ 1,176	\$ 382	\$ 2,298	\$ (47,751)	\$ 182
GAAP research and development (R&D) expense	\$ 23,749	\$ 16,553	\$ 13,508	\$ 34,582	\$ 48,788	\$ 29,065	\$ 24,220	\$ 22,433	\$ 25,929	\$ 28,148	\$ 88,392	\$ 124,506
Stock-based compensation expense	(11,667)	(5,456)	(4,949)	(5,337)	(6,554)	(7,303)	(5,914)	(5,082)	(6,355)	(6,941)	(27,409)	(24,853)
Amortization of intangible assets	-	-	-	(277)	(416)	(415)	(417)	(416)	(416)	(415)	(277)	(1,664)
Non-GAAP R&D expense	\$ 12,082	\$ 11,097	\$ 8,559	\$ 28,968	\$ 41,818	\$ 21,347	\$ 17,889	\$ 16,935	\$ 19,158	\$ 20,792	\$ 60,706	\$ 97,989
GAAP selling, general and administrative (SG&A) expense	\$ 27,274	\$ 16,688	\$ 17,245	\$ 17,807	\$ 19,548	\$ 20,884	\$ 20,744	\$ 13,135	\$ 16,892	\$ 17,527	\$ 79,014	\$ 74,311
Stock-based compensation expense	(16,539)	(7,932)	(5,929)	(5,824)	(6,206)	(10,534)	(10,707)	(5,001)	(5,538)	(6,825)	(36,224)	(32,448)
Amortization of intangible assets	-	-	-	(536)	(756)	(774)	(774)	(773)	(774)	(773)	(536)	(3,077)
Legal expenses related to shareholder lawsuit, net	(139)	(82)	(167)	(463)	(142)	(523)	(801)	2,007	(1,404)	(1,247)	(851)	541
Acquisition cost	-	-	(1,115)	(158)	-	-	-	-	-	(664)	(1,273)	-
Non-GAAP SG&A expense	\$ 10,596	\$ 8,674	\$ 10,034	\$ 10,826	\$ 12,444	\$ 9,053	\$ 8,462	\$ 9,368	\$ 9,176	\$ 8,018	\$ 40,130	\$ 39,327
GAAP operating expenses	\$ 51,023	\$ 37,652	\$ 33,774	\$ 52,389	\$ 68,336	\$ 88,095	\$ 48,625	\$ 35,568	\$ 42,821	\$ 45,675	\$ 174,838	\$ 240,624
Stock-based compensation expense included in R&D expense	(11,667)	(5,456)	(4,949)	(5,337)	(6,554)	(7,303)	(5,914)	(5,082)	(6,355)	(6,941)	(27,409)	(24,853)
Stock-based compensation expense included in SG&A expense	(16,539)	(7,932)	(5,929)	(5,824)	(6,206)	(10,534)	(10,707)	(5,001)	(5,538)	(6,825)	(36,224)	(32,448)
Amortization of intangible assets	-	-	-	(813)	(1,172)	(1,189)	(1,191)	(1,189)	(1,190)	(1,188)	(813)	(4,741)
Impairment of equipment	-	(4,411)	-	-	-	-	-	-	-	-	(4,411)	-
Restructuring cost	-	-	(3,021)	-	-	(38,146)	(3,661)	-	-	-	(3,021)	(41,807)
Legal expenses related to shareholder lawsuit, net	(139)	(82)	(167)	(463)	(142)	(523)	(801)	2,007	(1,404)	(1,247)	(851)	541
Acquisition cost	-	-	(1,115)	(158)	-	-	-	-	-	(664)	(1,273)	-
Non-GAAP operating expenses	\$ 22,678	\$ 19,771	\$ 18,593	\$ 39,794	\$ 54,262	\$ 30,400	\$ 26,351	\$ 26,303	\$ 28,334	\$ 28,810	\$ 100,836	\$ 137,316

## Appendix 1 (continued) - Reconciliation of GAAP to Non-GAAP Financial Measures

Other Non-GAAP Financial Measures Reconciliation (in thousands, except Share and per Share amounts)	Unaudited										Unaudited	
	Q1-23	Q2-23	Q3-23	Q4-23	Q1-24	Q2-24	Q3-24	Q4-24	Q1-25	Q2-25	FY23	FY24
GAAP loss from operations	\$ (63,250)	\$ (51,845)	\$ (50,383)	\$ (64,777)	\$ (70,136)	\$ (88,750)	\$ (49,267)	\$ (34,516)	\$ (42,560)	\$ (43,733)	\$ (230,255)	\$ (242,669)
Stock-based compensation expense	29,157	15,042	13,274	11,620	12,760	17,932	16,722	10,207	12,014	14,122	69,093	57,621
Amortization of intangible assets	-	-	-	813	1,172	1,189	1,191	1,189	1,190	1,188	813	4,741
Inventory step-up	-	-	-	2,206	1,907	-	-	-	-	-	2,206	1,907
Impairment of equipment	-	4,411	-	-	-	-	-	-	-	-	4,411	-
Restructuring cost	-	-	3,021	-	-	38,146	3,661	-	-	-	3,021	41,807
Legal expenses related to shareholder lawsuit, net	139	82	167	463	142	523	801	(2,007)	1,404	1,247	851	(541)
Acquisition cost	-	-	1,115	158	-	-	-	-	-	664	1,273	-
Non-GAAP loss from operations	\$ (33,954)	\$ (32,310)	\$ (32,806)	\$ (49,517)	\$ (54,155)	\$ (30,960)	\$ (26,892)	\$ (25,127)	\$ (27,952)	\$ (26,512)	\$ (148,587)	\$ (137,134)
GAAP net loss attributable to Enovix	\$ (73,603)	\$ (64,306)	\$ (16,185)	\$ (59,977)	\$ (46,368)	\$ (115,872)	\$ (22,536)	\$ (37,465)	\$ (23,510)	\$ (44,528)	\$ (214,071)	\$ (222,241)
Stock-based compensation expense	29,157	15,042	13,274	11,620	12,760	17,932	16,722	10,207	12,014	14,122	69,093	57,621
Change in fair value of common stock warrants	12,840	14,340	(31,320)	(2,040)	(21,120)	33,660	(29,899)	5,115	(15,796)	5,885	(6,180)	(12,244)
Inventory step-up	-	-	-	2,206	1,907	-	-	-	-	-	2,206	1,907
Amortization of intangible assets	-	-	-	813	1,172	1,189	1,191	1,189	1,190	1,188	813	4,741
Impairment of equipment	-	4,411	-	-	-	-	-	-	-	-	4,411	-
Restructuring cost	-	-	3,021	-	-	38,146	3,661	-	-	-	3,021	41,807
Legal expenses related to shareholder lawsuit, net	139	82	167	463	142	523	801	(2,007)	1,404	1,247	851	(541)
Acquisition cost	-	-	1,115	158	-	-	-	-	-	664	1,273	-
Gain on bargain purchase of assets	-	-	-	-	-	-	-	-	-	(4,761)	-	-
Import duty forgiveness	-	-	-	-	-	-	-	-	(2,431)	-	-	-
Non-GAAP net loss attributable to Enovix shareholders	\$ (31,467)	\$ (30,431)	\$ (29,928)	\$ (46,757)	\$ (51,507)	\$ (24,422)	\$ (30,060)	\$ (22,961)	\$ (27,129)	\$ (26,183)	\$ (138,583)	\$ (128,950)
GAAP net loss per share attributable to Enovix, basic	\$ (0.44)	\$ (0.38)	\$ (0.10)	\$ (0.34)	\$ (0.26)	\$ (0.63)	\$ (0.12)	\$ (0.19)	\$ (0.12)	\$ (0.22)	\$ (1.27)	\$ (1.19)
GAAP weighted average number of common shares outstanding, basic	165.4	167.0	169.9	176.1	178.7	183.3	187.8	196.6	203.4	204.8	169.1	186.1
GAAP net loss per share attributable to Enovix, diluted	\$ (0.44)	\$ (0.38)	\$ (0.28)	\$ (0.34)	\$ (0.26)	\$ (0.63)	\$ (0.28)	\$ (0.19)	\$ (0.12)	\$ (0.22)	\$ (1.30)	\$ (1.19)
GAAP weighted average number of common shares outstanding, diluted	165.4	167.0	171.4	176.1	178.7	183.3	188.0	196.6	203.4	204.8	169.6	186.1
Non-GAAP net loss per share attributable to Enovix, basic	\$ (0.19)	\$ (0.18)	\$ (0.18)	\$ (0.27)	\$ (0.29)	\$ (0.13)	\$ (0.16)	\$ (0.12)	\$ (0.13)	\$ (0.13)	\$ (0.82)	\$ (0.69)
GAAP weighted average number of common shares outstanding, basic	165.4	167.0	169.9	176.1	178.7	183.3	187.8	196.6	203.4	204.8	169.1	186.1
Non-GAAP net loss per share attributable to Enovix, diluted	\$ (0.19)	\$ (0.18)	\$ (0.17)	\$ (0.27)	\$ (0.29)	\$ (0.13)	\$ (0.16)	\$ (0.12)	\$ (0.13)	\$ (0.13)	\$ (0.82)	\$ (0.69)
GAAP weighted average number of common shares outstanding, diluted	165.4	167.0	171.4	176.1	178.7	183.3	188.0	196.6	203.4	204.8	169.6	186.1